Sweet's syndrome in a severely neutropenic patient during therapy with recombinant human granulocyte colony-stimulating factor

J Formos Med Assoc. 1997 Apr;96(4):276-9.

Abstract

We report a new case of Sweet's syndrome (SS) associated with recombinant human granulocyte colony-stimulating factor (rHuG-CSF) therapy in a patient with acute myelogenous leukemia (AML). The patient developed a fever in association with multiple tender, purpuric and pustular skin lesions and swelling of both calves after receiving rHuG-CSF 3 micrograms/kg/d for 4 days. The absolute neutrophil count was 0.55 x 10(9)/L at onset. A skin biopsy revealed a dense neutrophilic infiltration in the dermis without evidence of vasculitis or infection. All skin and calf lesions regressed within 1 week after prednisolone therapy. Physicians should be aware of potential neutrophil-mediated dermatoses in patients with severe neutropenia on rHuG-CSF treatment.

Publication types

  • Case Reports

MeSH terms

  • Granulocyte Colony-Stimulating Factor / adverse effects*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Male
  • Middle Aged
  • Neutropenia / complications*
  • Neutropenia / diagnosis
  • Recombinant Proteins
  • Sweet Syndrome / complications
  • Sweet Syndrome / drug therapy
  • Sweet Syndrome / etiology*
  • Sweet Syndrome / pathology

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor